<table id="t2" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2: Potentially Significant Drug Interactions: Alterations in Dose or Regimen May Be Recommended Based on Drug Interaction Trials or Predicted Interaction</caption>
<col align="left" valign="top" width="30%"></col>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="45%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule">Concomitant Drug<br/>Class:<br/>Drug Name</th>
<th stylecode="Rrule">Effect on Concentration of Darunavir, Cobicistat, or Concomitant Drug</th>
<th stylecode="Rrule">Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV-1 Antiviral Agents: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">didanosine</td>
<td stylecode="Rrule">↔ darunavir<br/>↔ cobicistat<br/>↔ didanosine</td>
<td stylecode="Rrule" valign="middle">Didanosine should be administered one hour before or two hours after PREZCOBIX (administered with food).</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV-1 Antiviral Agents: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">efavirenz,</td>
<td stylecode="Rrule">↓ cobicistat<br/>↓ darunavir</td>
<td stylecode="Rrule">Coadministration with efavirenz is not recommended because it may result in loss of therapeutic effect and development of resistance to darunavir.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">etravirine,</td>
<td stylecode="Rrule">↓ cobicistat<br/>darunavir: effect unknown</td>
<td stylecode="Rrule">Coadministration with etravirine is not recommended because it may result in loss of therapeutic effect and development of resistance to darunavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">neviraprine</td>
<td stylecode="Rrule">↓ cobicistat<br/>darunavir: effect unknown</td>
<td stylecode="Rrule">Coadministration with nevirapine is not recommended because it may result in loss of therapeutic effect and development of resistance to darunavir.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV-1 Antiviral Agents: CCR5 co-receptor antagonists</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">maraviroc</td>
<td stylecode="Rrule">↑ maraviroc</td>
<td stylecode="Rrule">Maraviroc is a substrate of CYP3A. When coadministered with PREZCOBIX, patients should receive maraviroc 150 mg twice daily.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Other Agents</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antiarrhythmics:</content>
<br/>e.g.<br/>amiodarone,<br/>disopyramide,<br/>flecainide,<br/>lidocaine (systemic),<br/>mexiletine,<br/>propafenone,<br/>quinidine,</td>
<td stylecode="Rrule">↑ antiarrhythmics</td>
<td stylecode="Rrule">Clinical monitoring is recommended upon coadministration with antiarrhythmics.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">digoxin</td>
<td stylecode="Rrule">↑ digoxin</td>
<td stylecode="Rrule">When coadministering with digoxin, titrate the digoxin dose and monitor digoxin concentrations.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antibacterial Agents</content>
<br/>clarithromycin,<br/>erythromycin,<br/>telithromycin</td>
<td stylecode="Rrule">↑ darunavir<br/>↑ cobicistat<br/>↑ antibacterial</td>
<td stylecode="Rrule">Consider alternative antibiotics with concomitant use of PREZCOBIX.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticancer Agents:</content>
<br/>dasatinib,<br/>nilotinib,</td>
<td stylecode="Rrule">↑ anticancer agent</td>
<td stylecode="Rrule">A decrease in the dosage or an adjustment of the dosing interval of dasatinib or nilotinib may be necessary when coadministered with PREZCOBIX. Consult the dasatinib and nilotinib prescribing information for dosing instructions.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">vinblastine,<br/>vincristine</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">For vincristine and vinblastine, consider temporarily withholding the cobicistat-containing antiretroviral regimen in patients who develop significant hematologic or gastrointestinal side effects when PREZCOBIX is administered concurrently with vincristine or vinblastine. If the antiretroviral regimen must be withheld for a prolonged period, consider initiating a revised regimen that does not include a CYP3A or P-gp inhibitor.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticoagulants:</content>
<br/>apixaban,</td>
<td stylecode="Rrule">↑ anticoagulant</td>
<td stylecode="Rrule">Concomitant use of apixaban is not recommended.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">dabigatran etexilate,</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">Concomitant use with dabigatran etexilate is not recommended in specific renal impairment groups (depending on the indication). Please see the dabigatran US prescribing information for specific recommendations.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">rivaroxaban,</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">Coadministration with rivaroxaban is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">warfarin</td>
<td stylecode="Rrule">warfarin: effect unknown</td>
<td stylecode="Rrule">Monitor the international normalized ratio (INR) when coadministering with warfarin.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticonvulsants that induce CYP3A:</content>
<br/>e.g. carbamazepine,<br/>oxcarbazepine, phenobarbital,<br/>phenytoin</td>
<td stylecode="Rrule">↓ cobicistat<br/>darunavir effect unknown</td>
<td stylecode="Rrule">Consider alternative anticonvulsant or antiretroviral therapy to avoid potential changes in exposures. If coadministration is necessary, monitor for lack or loss of virologic response.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">phenobarbital,<br/>phenytoin</td>
<td stylecode="Rrule">phenobarbital: effect unknown<br/>phenytoin: effect unknown</td>
<td stylecode="Rrule">Monitor phenobarbital or phenytoin concentrations.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticonvulsants that are metabolized by CYP3A:</content>
<br/>e.g. clonazepam, carbamazepine</td>
<td stylecode="Rrule">↑ carbamazepine<br/>↑ clonazepam</td>
<td stylecode="Rrule">Clinical monitoring is recommended.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antidepressants:</content>
<br/>Selective Serotonin Reuptake Inhibitors (SSRIs):<br/>e.g.<br/>paroxetine,<br/>sertraline,</td>
<td stylecode="Rrule">SSRIs: effects unknown<br/>↑ TCAs</td>
<td stylecode="Rrule">When coadministering with SSRIs, TCAs, or trazodone, careful dose titration of the antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitoring for antidepressant response are recommended.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Tricyclic Antidepressants (TCAs):<br/>e.g.<br/>amitriptyline,<br/>desipramine,<br/>imipramine,<br/>nortriptyline</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Other antidepressants:<br/>trazodone</td>
<td stylecode="Rrule">↑ trazodone<br/>
</td>
<td stylecode="Rrule"></td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antifungals:</content>
<br/>itraconazole,<br/>ketoconazole,<br/>posaconazole,</td>
<td stylecode="Rrule">↑ darunavir<br/>↑ cobicistat</td>
<td stylecode="Rrule">Monitor for increased darunavir or cobicistat adverse reactions.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">↑ itraconazole<br/>↑ ketoconazole<br/>↔ posaconazole (not studied)</td>
<td stylecode="Rrule">Specific dosing recommendations are not available for coadministration with itraconazole or ketoconazole. Monitor for increased itraconazole or ketoconazole adverse reactions.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">voriconazole</td>
<td stylecode="Rrule">Voriconazole: effects unknown</td>
<td stylecode="Rrule">Coadministration with voriconazole is not recommended unless benefit/risk assessment justifies the use of voriconazole.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anti-gout:</content>
<br/>colchicine</td>
<td stylecode="Rrule">↑ colchicine</td>
<td stylecode="Rrule">
<content stylecode="underline">Treatment of gout flares – coadministration of colchicine:</content>
<list listtype="unordered">
<item>
<caption>-</caption>0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Treatment course to be repeated no earlier than 3 days.</item>
</list>
<content stylecode="underline">Prophylaxis of gout flares – coadministration of colchicine:</content>
<list listtype="unordered">
<item>
<caption>-</caption>If the original regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day. If the original regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.</item>
</list>
<content stylecode="underline">Treatment of familial Mediterranean fever - coadministration of colchicine:</content>
<br/>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).<br/>Coadministration with colchicine is contraindicated in patients with renal or hepatic impairment [<content stylecode="italics">see <linkhtml href="#S4">Contraindications (4)</linkhtml>
</content>].</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antimalarial:</content>
<br/>artemether/lumefantrine<br/>
</td>
<td stylecode="Rrule">artemether: effect unknown<br/>lumefantrine: effect unknown</td>
<td stylecode="Rrule">Monitor for a potential decrease of antimalarial efficacy or potential QT prolongation.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antimycobacterials:</content>
<br/>rifabutin</td>
<td stylecode="Rrule">↑ rifabutin<br/>cobicistat: effects unknown<br/>darunavir: effects unknown</td>
<td stylecode="Rrule">When used in combination with PREZCOBIX, the recommended dose of rifabutin is 150 mg every other day. Monitor for rifabutin-associated adverse reactions including neutropenia and uveitis.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">rifapentine</td>
<td stylecode="Rrule">↓ darunavir</td>
<td stylecode="Rrule">Coadministration with rifapentine is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">β-Blockers:</content>
<br/>e.g.<br/>carvedilol,<br/>metoprolol,<br/>timolol</td>
<td stylecode="Rrule">↑ beta-blockers</td>
<td stylecode="Rrule">Clinical monitoring is recommended for coadministration with beta-blockers that are metabolized by CYP2D6.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Calcium Channel Blockers:</content>
<br/>e.g.<br/>amlodipine,<br/>diltiazem,<br/>felodipine,</td>
<td stylecode="Rrule">↑ calcium channel blockers</td>
<td stylecode="Rrule">Clinical monitoring is recommended for coadministration with calcium channel blockers metabolized by CYP3A.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">nifedipine,<br/>verapamil</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Corticosteroids (inhaled/nasal)<br/>metabolized by CYP3A:</content>
<br/>e.g.<br/>budesonide,<br/>fluticasone</td>
<td stylecode="Rrule">↑ corticosteroid</td>
<td stylecode="Rrule">Coadministration with inhaled or nasal fluticasone or other corticosteroids that are metabolized by CYP3A may result in reduced serum cortisol concentrations. Alternative corticosteroids should be considered, particularly for long-term use.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Corticosteroid systemic:<br/>e.g.</content>
<br/>dexamethasone</td>
<td stylecode="Rrule">↓ darunavir<br/>↓ cobicistat<br/>↑ corticosteroids</td>
<td stylecode="Rrule">Coadministration with dexamethasone or other corticosteroids that induce CYP3A may result in loss of therapeutic effect of and development of resistance to darunavir. Consider alternative corticosteroids.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Corticosteroids (systemic)<br/>metabolized by CYP3A:</content>
<br/>e.g.<br/>budesonide,<br/>prednisolone</td>
<td stylecode="Rrule">↑ corticosteroid</td>
<td stylecode="Rrule">Coadministration with corticosteroids that are metabolized by CYP3A, particularly for long-term use, may increase the risk for development of systemic corticosteroid effects including Cushing's syndrome and adrenal suppression. Consider the potential benefit of treatment versus the risk of systemic corticosteroid effects.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Endothelin receptor antagonists:</content>
<br/>bosentan</td>
<td stylecode="Rrule">↓ darunavir<br/>↓ cobicistat<br/>↑ bosentan</td>
<td stylecode="Rrule">
<content stylecode="underline">Initiation of bosentan in patients taking PREZCOBIX</content>:<br/>In patients who have been receiving PREZCOBIX for at least 10 days, start bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<br/>
<content stylecode="underline">Initiation of PREZCOBIX in patients on bosentan:</content>
<br/>Discontinue use of bosentan at least 36 hours prior to initiation of PREZCOBIX. After at least 10 days following the initiation of PREZCOBIX, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<br/>
<content stylecode="underline">Switching from darunavir coadministered with ritonavir to PREZCOBIX in patients on bosentan:</content>
<br/>Maintain bosentan dose.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Hepatitis C Virus (HCV) </content>
<br/>NS3-4A protease inhibitors:<br/>boceprevir,<br/>telaprevir,<br/>simeprevir</td>
<td stylecode="Rrule">darunavir: effects unknown<br/>boceprevir: effects unknown<br/>telaprevir: effects unknown<br/>↑ simeprevir</td>
<td stylecode="Rrule">No drug interaction data are available. Coadministration with boceprevir, simeprevir, or telaprevir is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HMG-CoA Reductase Inhibitors:</content>
<br/>e.g.<br/>atorvastatin,<br/>fluvastatin,<br/>pitavastatin,<br/>pravastatin,<br/>rosuvastatin</td>
<td stylecode="Rrule">↑ atorvastatin<br/>↑ fluvastatin<br/>↑ pravastatin<br/>↑ rosuvastatin<br/>pitavastatin: effect unknown<br/>
</td>
<td stylecode="Rrule">For atorvastatin, fluvastatin, pitavastatin<br/>pravastatin, and rosuvastatin, start with the lowest recommended dose and titrate while monitoring for safety <content stylecode="italics">[see <linkhtml href="#S4">Contraindications (4)</linkhtml>].</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Hormonal Contraceptives:</content>
<br/>progestin/estrogen</td>
<td stylecode="Rrule">progestin: effects unknown<br/>estrogen: effects unknown</td>
<td stylecode="Rrule">No data are available to make recommendations on coadministration with oral or other hormonal contraceptives. Additional or alternative (non-hormonal) forms of contraception should be considered.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Immunosuppressants:</content>
<br/>cyclosporine,<br/>sirolimus,<br/>tacrolimus</td>
<td stylecode="Rrule">↑ immunosuppressants</td>
<td stylecode="Rrule">These immunosuppressant agents are metabolized by CYP3A. Therapeutic drug monitoring is recommended with concomitant use.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Immunosuppressant/neoplastic: </content>
<br/>everolimus</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">Coadministration of everolimus and PREZCOBIX is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Inhaled beta agonist:</content>
<br/>salmeterol</td>
<td stylecode="Rrule">↑ salmeterol</td>
<td stylecode="Rrule">Coadministration with salmeterol is not recommended and may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Narcotic Analgesics metabolized by CYP3A:</content>
<br/>e.g.<br/>fentanyl,<br/>oxycodone</td>
<td stylecode="Rrule">↑ fentanyl<br/>↑ oxycodone</td>
<td stylecode="Rrule">Careful monitoring of therapeutic effects and adverse reactions associated with CYP3A-metabolized narcotic analgesics (including potentially fatal respiratory depression) is recommended with coadministration.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">tramadol</td>
<td stylecode="Rrule">↑ tramadol</td>
<td stylecode="Rrule">A dose decrease may be needed for tramadol with concomitant use.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Narcotic Analgesic for Treatment of Opioid Dependence:</content>
<br/>buprenorphine,<br/>buprenorphine/naloxone,<br/>methadone</td>
<td stylecode="Rrule">buprenorphine or buprenorphine/naloxone: effects unknown<br/>methadone: effects unknown</td>
<td stylecode="Rrule">
<content stylecode="underline">Initiation of buprenorphine, buprenorphine/naloxone or methadone in patients taking PREZCOBIX:</content>
<br/>Carefully titrate the dose of buprenorphine, buprenorphine/naloxone or methadone to the desired effect; use the lowest feasible initial or maintenance dose.<br/>
<content stylecode="underline">Initiation of PREZCOBIX in patients taking buprenorphine, buprenorphine/naloxone or methadone:</content>
<br/>A dose adjustment for buprenorphine, buprenorphine/naloxone or methadone may be needed. Monitor clinical signs and symptoms.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Neuroleptics:</content>
<br/>e.g.<br/>perphenazine,<br/>risperidone,<br/>thioridazine</td>
<td stylecode="Rrule">↑ neuroleptics</td>
<td stylecode="Rrule">A decrease in the dose of neuroleptics that are CYP3A- or CYP2D6- metabolized may be needed when coadministered with PREZCOBIX.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Phosphodiesterase PDE-5 inhibitors:</content>
<br/>e.g.<br/>avanafil,<br/>sildenafil,<br/>tadalafil,<br/>vardenafil</td>
<td stylecode="Rrule">↑ PDE-5 inhibitors</td>
<td stylecode="Rrule">Coadministration with avanafil is not recommended because a safe and effective avanafil dosage regimen has not been established.<br/>Coadministration with PDE-5 inhibitors may result in an increase in PDE-5 inhibitor-associated adverse reactions including hypotension, syncope, visual disturbances and priapism.<br/>Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH):<list listtype="unordered" stylecode="disc">
<item>Coadministration with sildenafil is contraindicated [<content stylecode="italics">see <linkhtml href="#S4">Contraindications (4)</linkhtml>
</content>].</item>
<item>The following dose adjustments are recommended for use of tadalafil with PREZCOBIX: <br/>
<content stylecode="italics">Initiation of tadalafil in patients taking PREZCOBIX:</content>
<br/>In patients receiving PREZCOBIX for at least one week, start tadalafil at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<br/>
<content stylecode="italics">Initiation of PREZCOBIX in patients taking tadalafil:</content>
<br/>Avoid use of tadalafil during the initiation of PREZCOBIX. Stop tadalafil at least 24 hours prior to starting PREZCOBIX. After at least one week following the initiation of PREZCOBIX, resume tadalafil at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.</item>
<item> Patients switching from darunavir coadministered with ritonavir to PREZCOBIX:<br/>Maintain tadalafil dose.</item>
</list>
<content stylecode="italics">Use of PDE-5 inhibitors for erectile dysfunction:</content>
<br/>Sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg dose in 72 hours, or tadalafil at a single dose not exceeding 10 mg dose in 72 hours can be used with increased monitoring for PDE-5 inhibitor-associated adverse reactions.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Sedatives/Hypnotics metabolized by CYP3A:</content>
<br/>e.g.<br/>buspirone,<br/>diazepam,<br/>estazolam</td>
<td stylecode="Rrule">↑ sedatives/hypnotics</td>
<td stylecode="Rrule">With concomitant use, titration is recommended with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for increased and prolonged effects or adverse reactions.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">parenterally administered midazolam,</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">Coadministration of parenteral midazolam should be done in a setting that ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dose reduction for parenteral midazolam should be considered, especially if more than a single dose of midazolam is administered.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">zoldipem</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">Coadministration with oral midazolam or triazolam is CONTRAINDICATED <content stylecode="italics">[see <linkhtml href="#S4">Contraindications (4.0)</linkhtml>]</content>.</td>
</tr>
</tbody>
</table>